May 23, 2023: Synthetic biology is a sector of biotechnology that focuses on merging technologies with biological life forms. Using Ai and gene-editing nanotechnologies, this sector also creates multi-species hybrid biotechnologies that mimic biological species and life forms.
In Q1 2023 (Jan-March), the total amount of private and government funding invested in the synthetic biology industry was $1.8 billion, of which $1.43 billion was in Health & Medicine with the US Military being the largest single investor by far.
The suite of synthetic biology nanotechnologies that humans are exposed to through food, beverages, medicine, cleaning supplies, cosmetics, and even clothing, includes mRNA technologies, lipid nanoparticle technologies, hydrogel, and other gene-editing nanotechnologies.
mRNA technology injections (aka ‘COVID-19 vaccines) were the entry point into the use of nanotechnologies in adults and children in order to merge human cells with non-human DNA and digital devices, per Dr. Robert Malone.
In March of 2023, the US Department of Defense financed $410 million for Resilience, a San Diego based biotech company, to produce synthetic biology technologies for use in humans, including mRNA nanotechnologies and vaccines.
Per a March 24, 2023, press release;
“National Resilience Inc. announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD).”
“The loan financing will support Resilience’s mission to establish significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA). This expanded capacity…will help secure the nation’s supply chain for vaccines and critical medicines, bolster pandemic preparedness and response, and help address a critical advanced manufacturing infrastructure shortage revealed by the COVID-19 pandemic. Part of the financing will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen the domestic supply chain, and increase the speed of vaccine supply.”
In comparison to the US Military’s Q1 2023 $410 million investment into Resiliense, the private equity sector raised $457 million in Q1 public stock offerings across six (6)companies, primarily for…
Read full story: US Military is the Largest Investor in mRNA Synthetic Biology
And please subscribe to The Kingston Report.